文献速递糖尿病

采用预防性药物清单对2年内药物费用及收入差异的影响:糖尿病转化自然实验(NEXT-D)研究

Effects of Adopting Preventive Drug Lists on Medication Costs and Disparities by Income Over 2 Years: A Natural Experiment for Translation in Diabetes (NEXT-D) Study.
PubMed 文献 · Diabetes Care · 2025-01-01

该准实验研究利用Optum去标识化数据库(2003年1月至2017年12月),比较5,582例转为预防性药物清单(PDL)覆盖的糖尿病患者与5,582例匹配的无PDL覆盖患者。结果显示,PDL组随访第2年所有药物自付费用较对照组下降29.7%(95%CI -36.0, -23.4%),高收入和低收入PDL成员在关键治疗类别中的自付费用均显著降低,且关键治疗类别的使用率显著增加。

要点

  • PDL组随访第2年所有药物自付费用较对照组下降29.7%(95%CI -36.0, -23.4%)。
  • 高收入和低收入PDL成员第2年所有药物自付费用降低约30%,关键治疗类别降低23%至67%。
  • 总体人群及高、低收入PDL成员的关键治疗类别使用率显著增加,范围分别为8%至15%和9%至50%。

核心结论

  • PDL是雇主和保险公司降低成员费用分担并鼓励增加重要药物使用的有效策略。
  • 对于糖尿病患者,尤其是低收入者,PDL覆盖带来了自付药物费用的持续大幅降低、药物使用增加以及部分更昂贵产品使用的增加。

研究设计与样本

  • 准实验研究,使用Optum去标识化Clinformatics Data Mart数据库(2003年1月至2017年12月)。
  • 干预组为5,582例12-64岁由雇主转为PDL覆盖的糖尿病患者;对照组为5,582例匹配的雇主未提供PDL的患者。
  • 结局包括所有药物和五种PDL覆盖治疗类别(口服降糖药、胰岛素、试纸、降压药、降脂药)的自付费用、标准化费用和30天配药量。

主要发现

  • PDL组随访第2年所有药物自付费用较对照组下降29.7%(95%CI -36.0, -23.4%)。
  • 高收入和低收入PDL成员第2年所有药物自付费用降低约30%,关键治疗类别降低23%至67%。
  • 总体人群关键治疗类别使用率增加8%至15%,高收入和低收入PDL成员增加9%至50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between preventive drug lists (PDLs) and changes in medication costs among patients with diabetes insured in commercial health plans over 2 follow-up years. RESEARCH DESIGN AND METHODS: We conducted a quasiexperimental study using the Optum deidentified Clinformatics Data Mart Database (January 2003 to December 2017). The intervention group included 5,582 patients with diabetes age 12-64 years switched by employers to PDL coverage; the control group included 5,582 matched patients whose employers offered no PDL. Outcomes included out-of-pocket costs, standardized costs, and 30-day fills for all medications because PDL-associated savings could be used to pay for medicines in other classes and for five therapeutic classes covered by the PDLs (oral diabetes medications, insulins, test strips, antihypertensive drugs, and lipid-lowering drugs). RESULTS: Pre- to post-out-of-pocket spending for all medications declined by 29.7% in follow-up year 2 (95% CI -36.0, -23.4%) among PDL members relative to control individuals. Higher-income and lower-income PDL members experienced significant reductions in out-of-pocket spending for all medications in year 2 (30%) and for key therapeutic classes (range -23 to -67%). We found significant increases in use of key therapeutic classes in the overall population (range 8-15%) and in higher-income and lower-income PDL members (range 9-50%). CONCLUSIONS: PDLs offer an effective strategy for employers and insurers to lower member cost sharing and encourage increased use of important medications to prevent or manage chronic illnesses. For patients with diabetes, especially those with lower incomes, PDL coverage resulted in substantial and persistent reductions in out-of-pocket medication costs, medication use increases, and some increased use of more expensive products.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lu CY, Argetsinger S, Lakoma M, et al. Effects of Adopting Preventive Drug Lists on Medication Costs and Disparities by Income Over 2 Years: A Natural Experiment for Translation in Diabetes (NEXT-D) Study. Diabetes Care. 2025. PMID: 39378179. doi:10.2337/dc24-0361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。